Cari­bou’s off-the-shelf CAR-T ther­a­py shows hints of dura­bil­i­ty in ear­ly cut of da­ta 

Cari­bou Bio­sciences shared an ear­ly cut of da­ta Thurs­day af­ter­noon that sug­gests its off-the shelf CAR-T ther­a­py for pa­tients with B cell lym­phoma could ri­val cur­rent­ly ap­proved CAR-T treat­ments.

In 16 pa­tients, sev­en were still in com­plete re­mis­sion six months af­ter re­ceiv­ing Cari­bou’s off-the-shelf CAR-T treat­ment, which is made from donor cells as op­posed to a pa­tient’s own cells like cur­rent­ly avail­able CAR-T ther­a­pies are. The first pa­tient treat­ed in the Phase I clin­i­cal tri­al, known as ANTLER, has been in com­plete re­mis­sion for two years.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER